Results 21 to 30 of about 45,062 (281)

Japanese encephalitis vaccine for travelers: risk-benefit reconsidered [PDF]

Journal of Travel Medicine, 2019
Bradley A. Connor, Davidson H. Hamer, Phyllis E. Kozarsky, Elaine C. Jong, Scott B. Halstead, Jay Keystone, Maria D. Mileno, Richard Dawood, Bonnie Rogers, William B. Bunn   +9 more
openalex   +2 more sources

Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9-12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial. [PDF]

Vaccine X, 2020
Capeding MR, Alberto E, Feser J, Mooney J, Tang Y, Audet SA, Beeler JA, Ellison DW, Zhang L, Letson GW, Neuzil KM, Marfin AA.   +11 more
europepmc   +2 more sources

Safety and dose-sparing effect of Japanese encephalitis vaccine administered by microneedle patch in uninfected, healthy adults (MNA-J): a randomised, partly blinded, active-controlled, phase 1 trial

The Lancet Microbe, 2022
Summary: Background: It is unclear whether microneedle vaccinations of Japanese encephalitis virus can induce sufficient neutralising antibodies and reduce the amount of vaccine needed.
Hiroaki Iwata, PhD, Kosuke Kakita, PhD, Keisuke Imafuku, MD, Shota Takashima, PhD, Naoya Haga, MD, Yasuyuki Yamaguchi, MD, Kenji Taguchi, MS, Takayoshi Oyamada, MS   +7 more
doaj   +1 more source

Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children. [PDF]

Hum Vaccin Immunother, 2018
Summary: Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency.
Chanthavanich P, Limkittikul K, Sirivichayakul C, Chokejindachai W, Hattasingh W, Pengsaa K, Surangsrirat S, Srisuwannaporn T, Kaewma B, Yoksan S, Jun G, Zhumu B.   +11 more
europepmc   +2 more sources

Safety of live attenuated Japanese encephalitis vaccine given at the age of 9 months in National Immunisation Programme of Sri Lanka

Ceylon Medical Journal, 2016
OBJECTIVES This study was designed to describe the safety profile of the single dose live attenuated Japanese encephalitis vaccine (LJEV) SA-14-14-2 given at the age of 9 months in the National Immunisation programme of Sri Lanka.
K Sanchayan, Rohini Fernandopulle, Anura Amarasinghe, S. N. Thiyahiny, Sarangarajan Ranganathan   +4 more
openalex   +3 more sources

Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012-2016. [PDF]

Vaccine, 2018
Walker WL, Hills SL, Miller ER, Fischer M, Rabe IB.   +4 more
europepmc   +2 more sources

Complete protection for mice conferred by a DNA vaccine based on the Japanese encephalitis virus P3 strain used to prepare the inactivated vaccine in China

Virology Journal, 2020
Background The incidence of Japanese encephalitis (JE) has been dramatically reduced in China after sufficient vaccine coverage. The live-attenuated Japanese encephalitis virus (JEV) vaccine SA14–14-2 is believed to have strongly contribute to this ...
Xiaoyan Zheng, Xiaozheng Yu, Yan Wang, Lance Turtle, Min Cui, Ran Wang, Chenghong Yin   +6 more
doaj   +1 more source

Phylogeography of Japanese encephalitis virus:genotype is associated with climate [PDF]

, 2013
The circulation of vector-borne zoonotic viruses is largely determined by the overlap in the geographical distributions of virus-competent vectors and reservoir hosts.
A Igarashi, A Oya, A Rambaut, A Rambaut, AB Sabin, AJ Auguste, AJ Drummond, AJ Drummond, AJ Schuh, AJ Schuh, AJ Schuh, Alan D. T. Barrett, Amy C. Morrison, Amy J. Schuh, Andrew J. Leigh Brown, B Shapiro, BJ Smith, D Martin, D Posada, DP Martin, DP Martin, EK Cruickshank, EL Buescher, EL Buescher, EL Buescher, EL Buescher, EL Buescher, FA Rey, FJ May, G Baele, GL Campbell, GM Jenkins, H Tsuchie, H Weissenbock, HS Hurlbut, HY Wang, J Fox, J Parker, JE Bryant, JH Nam, JL Wang, JM Smith, JN Hanna, L Lewis, L Rosen, L Rosen, L Rosen, M Gouy, M Padidam, MA Mohammed, MA Suchard, Melissa J. Ward, MH Li, N Nitatpattana, P Lemey, PD Uchil, PT Nga, PV Fulmali, R Takhampunya, RS Lanciotti, S Guindon, S Kumar, SE Sulkin, SE Sulkin, SL Kosakovsky Pond, SL Kosakovsky Pond, SL Pond, SL Pond, SP Ma, T Bakonyi, T Mitamura, T Solomon, TJ Chambers, WF Scherer, WF Scherer, WF Scherer, WM Hammon, WR Chen, WR Chen, WS Paul, XL Pan, Y Kobayashi, YX Li, YY Chen   +83 more
core   +11 more sources

Recommendations for the use of Japanese encephalitis vaccines

Pediatrics and Neonatology, 2020
Japanese encephalitis (JE) is a mosquito-borne viral infection which is prevalent in Taiwan. The virus circulates in an enzootic cycle in pigs which serve as amplifying hosts. Outbreaks typically occur during summer. A universal vaccination program using
Ping-Ing Lee, Yhu-Chering Huang, Kao-Pin Hwang, Ching-Chuan Liu, Cheng-Hsun Chiu, Po-Yen Chen, Chun-Yi Lu, Chih-Jung Chen, Luan-Yin Chang, Nan-Chang Chiu, Hsin Chi, Hsiao-Chuan Lin, Keh-Gong Wu, Yu-Huai Ho, Wu Sun, Tzou-Yien Lin   +15 more
doaj   +1 more source

Japanese Encephalitis DNA Vaccines with Epitope Modification Reduce the Induction of Cross-Reactive Antibodies against Dengue Virus and Antibody-Dependent Enhancement of Dengue Virus Infection

Vaccines, 2022
Infection with viruses belonging to the genus Flavivirus, such as Japanese encephalitis virus (JEV) and dengue virus (DENV), is a worldwide health problem. Vaccines against JEV and DENV are currently available.
Tomohiro Kotaki, Yurie Nagai, Atsushi Yamanaka, Eiji Konishi, Masanori Kameoka   +4 more
doaj   +1 more source